brentuximab vedotin
takeda,seagen
['echelon-1', 'echelon']
 dr. steven ansell from on the #asco22 phase 3 echelon-1 study. os benefits innovative therapy combos over soc in chl . #oncotwitter 
Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.